指南与共识糖尿病肥胖与代谢综合征

强化降低LDL胆固醇治疗超越现行推荐预防主要血管事件:327037例随机试验的系统综述与荟萃分析

Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants.
指南 / 共识 · Lancet Diabetes Endocrinol · 2020-01-01

低心血管风险及年轻患者相对风险降低更明显。

要点

  • 每降低1 mmol/L LDL胆固醇,主要血管事件风险降低19%。
  • 获益与基线LDL水平、糖尿病及慢性肾病状态无关。
  • 低10年ASCVD风险及年轻患者相对风险降低更显著。

核心结论

  • 每降低1 mmol/L LDL胆固醇,主要血管事件风险相对降低19%,且独立于基线LDL水平、糖尿病或慢性肾病。
  • 低心血管风险和年轻患者可能有相似的相对风险降低,未来研究应探讨早期干预的潜在获益。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane对照试验中心注册库至2019年6月15日。
  • 纳入他汀、依折麦布和PCSK9抑制剂的随机对照试验,要求至少1000患者年随访。

临床怎么用

  • 强化降LDL治疗的主要血管事件获益不受基线LDL水平限制。
  • 糖尿病或慢性肾病患者同样可从每1 mmol/L LDL降低中获益。
  • 年轻及低心血管风险患者可能从早期降LDL干预中获益。

局限性

  • 研究未报告具体局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefits of LDL cholesterol-lowering treatment for the prevention of atherosclerotic cardiovascular disease are well established. However, the extent to which these effects differ by baseline LDL cholesterol, atherosclerotic cardiovascular disease risk, and the presence of comorbidities remains uncertain. METHODS: We did a systematic literature search (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, from inception up to June 15, 2019) for randomised controlled trials of statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors with at least 1000 patient-years of follow-up. Random-effects meta-analysis and meta-regressions were done to assess for risk of major vascular events (a composite of cardiovascular mortality, non-fatal myocardial infarction, non-fatal ischaemic stroke, or coronary revascularisation) per 1 mmol/L (38·7 mg/dL) reduction in LDL cholesterol concentrations. FINDINGS: 327 037 patients from 52 studies were included in the meta-analysis. Each 1 mmol/L reduction in LDL cholesterol was associated with a 19% relative risk (RR) reduction for major vascular events (RR 0·81 [95% CI 0·78-0·84]; p<0·0001). Similar reductions (per 1 mmol/L reduction in LDL cholesterol) were found in trials with participants with LDL cholesterol 2·60 mmol/L or lower, 2·61-3·40 mmol/L, 3·41-4·10 mmol/L, and more than 4·1 mmol/L (p=0·232 for interaction); and in a subgroup of patients who all had a baseline LDL cholesterol less than 2·07 mmol/L (80 mg/dL; RR 0·83 [95% CI 0·75-0·92]; p=0·001). We found greater RR reductions in patients at lower 10-year atherosclerotic cardiovascular disease risk (change in RR per 10% lower 10-year atherosclerotic cardiovascular disease 0·97 [95% CI 0·95-0·98]; p<0·0001) and in patients at younger age across a mean age of 50-75 years (change in RR per 10 years younger age 0·92 [0·83-0·97]; p=0·015). We found no difference in RR reduction for participants with or without diabetes (p=0·878 for interaction) and chronic kidney disease (p=0·934 for interaction). INTERPRETATION: For each 1 mmol/L LDL cholesterol lowering, the risk reduction of major vascular events is independent of the starting LDL cholesterol or the presence of diabetes or chronic kidney disease. Patients at lower cardiovascular risk and younger age might have a similar relative reduction in risk with LDL-cholesterol lowering therapies and future studies should investigate the potential benefits of earlier intervention. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020. PMID: 31862150. doi:10.1016/S2213-8587(19)30388-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。